| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 331 | 2023 | 2207 | 20.460 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 166 | 2023 | 963 | 16.400 |
Why?
|
| ErbB Receptors | 67 | 2023 | 557 | 6.710 |
Why?
|
| Antineoplastic Agents | 100 | 2023 | 1893 | 6.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 91 | 2023 | 1361 | 5.910 |
Why?
|
| Carcinoma, Small Cell | 103 | 2008 | 159 | 5.210 |
Why?
|
| Quinazolines | 37 | 2016 | 241 | 4.660 |
Why?
|
| Small Cell Lung Carcinoma | 13 | 2023 | 77 | 4.610 |
Why?
|
| Protein Kinase Inhibitors | 32 | 2023 | 790 | 3.440 |
Why?
|
| Paclitaxel | 28 | 2011 | 192 | 2.620 |
Why?
|
| Carboplatin | 24 | 2019 | 139 | 2.390 |
Why?
|
| Guanine | 11 | 2007 | 76 | 2.190 |
Why?
|
| Molecular Targeted Therapy | 13 | 2019 | 348 | 2.000 |
Why?
|
| Glutamates | 11 | 2007 | 59 | 2.000 |
Why?
|
| Neoplasm Staging | 63 | 2018 | 1178 | 1.940 |
Why?
|
| Adenocarcinoma | 30 | 2017 | 799 | 1.870 |
Why?
|
| Humans | 510 | 2023 | 115741 | 1.710 |
Why?
|
| Antibodies, Monoclonal | 42 | 2018 | 1265 | 1.640 |
Why?
|
| Biomarkers, Tumor | 35 | 2021 | 1048 | 1.590 |
Why?
|
| Neoadjuvant Therapy | 9 | 2023 | 301 | 1.570 |
Why?
|
| Deoxycytidine | 11 | 2004 | 140 | 1.560 |
Why?
|
| Taxoids | 13 | 2013 | 94 | 1.490 |
Why?
|
| Antimetabolites, Antineoplastic | 9 | 2007 | 83 | 1.440 |
Why?
|
| Skin Neoplasms | 55 | 2010 | 761 | 1.440 |
Why?
|
| Mutation | 29 | 2023 | 3364 | 1.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 22 | 2018 | 1147 | 1.360 |
Why?
|
| Clinical Trials as Topic | 48 | 2019 | 941 | 1.350 |
Why?
|
| Receptor, ErbB-2 | 11 | 2019 | 302 | 1.340 |
Why?
|
| Lymphoma | 47 | 1991 | 178 | 1.330 |
Why?
|
| Combined Modality Therapy | 52 | 2023 | 1127 | 1.310 |
Why?
|
| Antineoplastic Agents, Phytogenic | 10 | 2007 | 181 | 1.280 |
Why?
|
| Etoposide | 25 | 2023 | 149 | 1.240 |
Why?
|
| Survival Analysis | 33 | 2019 | 1219 | 1.160 |
Why?
|
| Carcinoma, Squamous Cell | 21 | 2023 | 577 | 1.160 |
Why?
|
| Sezary Syndrome | 36 | 1996 | 43 | 1.130 |
Why?
|
| Cisplatin | 28 | 2018 | 263 | 1.100 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2023 | 638 | 1.090 |
Why?
|
| Protein-Tyrosine Kinases | 9 | 2023 | 396 | 1.080 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 9 | 2010 | 40 | 1.070 |
Why?
|
| Mycosis Fungoides | 38 | 1996 | 61 | 1.040 |
Why?
|
| Erlotinib Hydrochloride | 12 | 2015 | 65 | 1.020 |
Why?
|
| Aged | 135 | 2023 | 19294 | 1.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2023 | 667 | 0.990 |
Why?
|
| Bradykinin | 9 | 2005 | 46 | 0.980 |
Why?
|
| In Situ Hybridization, Fluorescence | 21 | 2018 | 310 | 0.970 |
Why?
|
| Vinblastine | 7 | 2003 | 61 | 0.970 |
Why?
|
| Precision Medicine | 4 | 2018 | 344 | 0.960 |
Why?
|
| Immunotherapy | 13 | 2020 | 479 | 0.950 |
Why?
|
| Middle Aged | 164 | 2023 | 27069 | 0.940 |
Why?
|
| Proto-Oncogene Proteins | 15 | 2023 | 609 | 0.900 |
Why?
|
| Prognosis | 52 | 2019 | 3343 | 0.890 |
Why?
|
| Folic Acid Antagonists | 4 | 2005 | 8 | 0.890 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2018 | 216 | 0.870 |
Why?
|
| Tumor Cells, Cultured | 29 | 2014 | 850 | 0.850 |
Why?
|
| Male | 200 | 2023 | 56050 | 0.840 |
Why?
|
| Gene Dosage | 10 | 2018 | 129 | 0.830 |
Why?
|
| Female | 192 | 2023 | 60018 | 0.810 |
Why?
|
| Survival Rate | 23 | 2020 | 1651 | 0.790 |
Why?
|
| Neutropenia | 11 | 2022 | 127 | 0.780 |
Why?
|
| Liposomes | 2 | 2022 | 149 | 0.770 |
Why?
|
| Immunohistochemistry | 24 | 2020 | 1642 | 0.760 |
Why?
|
| Gene Amplification | 9 | 2019 | 96 | 0.750 |
Why?
|
| Pemetrexed | 13 | 2016 | 27 | 0.740 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 10 | 2022 | 225 | 0.730 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2015 | 334 | 0.710 |
Why?
|
| Enzyme Inhibitors | 9 | 2016 | 757 | 0.710 |
Why?
|
| Brain Neoplasms | 18 | 2023 | 980 | 0.700 |
Why?
|
| Smoking | 19 | 2019 | 1457 | 0.700 |
Why?
|
| Retirement | 1 | 2020 | 25 | 0.680 |
Why?
|
| Treatment Outcome | 41 | 2023 | 9162 | 0.660 |
Why?
|
| Pathologists | 1 | 2019 | 15 | 0.660 |
Why?
|
| Antigens, Neoplasm | 13 | 2009 | 223 | 0.620 |
Why?
|
| Tubulin Modulators | 1 | 2018 | 9 | 0.610 |
Why?
|
| T-Lymphocytes | 54 | 2020 | 1756 | 0.610 |
Why?
|
| Furans | 1 | 2018 | 22 | 0.610 |
Why?
|
| Randomized Controlled Trials as Topic | 20 | 2018 | 1218 | 0.600 |
Why?
|
| Ketones | 1 | 2018 | 44 | 0.590 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 36 | 0.560 |
Why?
|
| Aged, 80 and over | 33 | 2019 | 6423 | 0.560 |
Why?
|
| Sputum | 10 | 2019 | 290 | 0.560 |
Why?
|
| Aurora Kinase B | 1 | 2016 | 7 | 0.550 |
Why?
|
| Thymidylate Synthase | 4 | 2005 | 11 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-met | 6 | 2020 | 67 | 0.540 |
Why?
|
| Sulindac | 5 | 2007 | 17 | 0.540 |
Why?
|
| Pneumonectomy | 3 | 2015 | 126 | 0.540 |
Why?
|
| Interferon Type I | 12 | 1995 | 129 | 0.530 |
Why?
|
| Medical Oncology | 5 | 2003 | 230 | 0.520 |
Why?
|
| Awards and Prizes | 1 | 2016 | 56 | 0.520 |
Why?
|
| Neoplasm Proteins | 5 | 2009 | 385 | 0.520 |
Why?
|
| Organophosphates | 1 | 2016 | 90 | 0.520 |
Why?
|
| Gene Rearrangement | 8 | 2018 | 135 | 0.510 |
Why?
|
| Adult | 119 | 2023 | 30789 | 0.510 |
Why?
|
| Cell Line, Tumor | 18 | 2019 | 2751 | 0.500 |
Why?
|
| Dose-Response Relationship, Drug | 21 | 2016 | 1870 | 0.490 |
Why?
|
| Genomics | 3 | 2020 | 646 | 0.470 |
Why?
|
| Neoplasms | 10 | 2010 | 2118 | 0.470 |
Why?
|
| Chemoprevention | 5 | 2019 | 88 | 0.470 |
Why?
|
| Cell Cycle | 11 | 2015 | 546 | 0.460 |
Why?
|
| Esophagitis | 3 | 2012 | 65 | 0.440 |
Why?
|
| Cadherins | 6 | 2012 | 175 | 0.440 |
Why?
|
| Genes, erbB-1 | 6 | 2015 | 18 | 0.440 |
Why?
|
| Precancerous Conditions | 6 | 2018 | 156 | 0.440 |
Why?
|
| Disease Progression | 14 | 2022 | 2423 | 0.420 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 175 | 0.420 |
Why?
|
| Mice, Nude | 18 | 2017 | 639 | 0.400 |
Why?
|
| Melanoma | 5 | 2022 | 651 | 0.400 |
Why?
|
| Genes, erbB-2 | 7 | 2017 | 26 | 0.400 |
Why?
|
| Disease-Free Survival | 11 | 2018 | 621 | 0.390 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2004 | 314 | 0.390 |
Why?
|
| Pyridines | 6 | 2013 | 425 | 0.380 |
Why?
|
| Neuropeptides | 6 | 1998 | 65 | 0.380 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 9 | 2019 | 228 | 0.380 |
Why?
|
| Drug Administration Schedule | 18 | 2011 | 724 | 0.380 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 362 | 0.380 |
Why?
|
| Cell Division | 22 | 2007 | 759 | 0.370 |
Why?
|
| Bronchi | 7 | 2018 | 250 | 0.370 |
Why?
|
| Neoplasm Metastasis | 15 | 2019 | 526 | 0.370 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 40 | 0.360 |
Why?
|
| Head and Neck Neoplasms | 4 | 2009 | 425 | 0.360 |
Why?
|
| Esophagus | 1 | 2012 | 226 | 0.360 |
Why?
|
| Acrylamides | 2 | 2022 | 43 | 0.360 |
Why?
|
| Global Health | 1 | 2012 | 290 | 0.360 |
Why?
|
| Time Factors | 32 | 2018 | 6171 | 0.350 |
Why?
|
| Animals | 66 | 2019 | 32104 | 0.350 |
Why?
|
| Ribonucleotide Reductases | 3 | 2004 | 21 | 0.350 |
Why?
|
| Early Detection of Cancer | 6 | 2021 | 340 | 0.340 |
Why?
|
| Genotype | 2 | 2014 | 1787 | 0.340 |
Why?
|
| Signal Transduction | 17 | 2017 | 4541 | 0.340 |
Why?
|
| Cell Proliferation | 9 | 2018 | 2194 | 0.340 |
Why?
|
| Drug Screening Assays, Antitumor | 9 | 2009 | 180 | 0.340 |
Why?
|
| Fever | 5 | 2001 | 280 | 0.340 |
Why?
|
| Predictive Value of Tests | 12 | 2014 | 1825 | 0.340 |
Why?
|
| Drug Delivery Systems | 2 | 2010 | 301 | 0.340 |
Why?
|
| Phosphorylation | 6 | 2016 | 1571 | 0.330 |
Why?
|
| Drug Monitoring | 1 | 2010 | 184 | 0.330 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 139 | 0.320 |
Why?
|
| Calcium | 6 | 2002 | 1103 | 0.320 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2009 | 104 | 0.320 |
Why?
|
| Salvage Therapy | 2 | 2007 | 128 | 0.320 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2019 | 704 | 0.310 |
Why?
|
| Pyrazoles | 5 | 2013 | 362 | 0.310 |
Why?
|
| Drug Therapy, Combination | 27 | 2002 | 962 | 0.310 |
Why?
|
| Biomarkers | 4 | 2023 | 3471 | 0.310 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2001 | 72 | 0.300 |
Why?
|
| Mass Screening | 5 | 2020 | 1024 | 0.300 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 137 | 0.300 |
Why?
|
| Flow Cytometry | 14 | 2006 | 1083 | 0.290 |
Why?
|
| Meta-Analysis as Topic | 6 | 2017 | 161 | 0.290 |
Why?
|
| Mesothelioma | 3 | 2004 | 31 | 0.290 |
Why?
|
| Neoplasms, Experimental | 4 | 2002 | 153 | 0.290 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1997 | 38 | 0.280 |
Why?
|
| Leukemia | 16 | 2018 | 209 | 0.280 |
Why?
|
| Camptothecin | 5 | 2017 | 97 | 0.280 |
Why?
|
| Receptors, KIR | 2 | 2018 | 92 | 0.280 |
Why?
|
| ras Proteins | 7 | 2014 | 138 | 0.280 |
Why?
|
| Mice | 32 | 2019 | 15052 | 0.280 |
Why?
|
| Protease Inhibitors | 2 | 2004 | 101 | 0.270 |
Why?
|
| Oligopeptides | 4 | 2005 | 248 | 0.270 |
Why?
|
| Interferons | 7 | 1995 | 152 | 0.270 |
Why?
|
| Lung | 14 | 2023 | 3673 | 0.270 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2023 | 332 | 0.270 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2018 | 178 | 0.270 |
Why?
|
| Bradykinin Receptor Antagonists | 2 | 2002 | 4 | 0.260 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2015 | 192 | 0.260 |
Why?
|
| Carcinoma in Situ | 4 | 2019 | 44 | 0.250 |
Why?
|
| Recombinant Proteins | 14 | 1998 | 1243 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2017 | 863 | 0.250 |
Why?
|
| Apoptosis | 9 | 2018 | 2377 | 0.250 |
Why?
|
| Biomedical Research | 3 | 2010 | 589 | 0.250 |
Why?
|
| Thrombocytopenia | 7 | 2000 | 175 | 0.250 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2002 | 72 | 0.240 |
Why?
|
| Genes, ras | 5 | 2015 | 91 | 0.240 |
Why?
|
| Antigens, Surface | 10 | 1988 | 151 | 0.240 |
Why?
|
| Gene Expression Profiling | 8 | 2016 | 1537 | 0.240 |
Why?
|
| Tankyrases | 2 | 2016 | 12 | 0.240 |
Why?
|
| Liver Neoplasms | 7 | 2015 | 521 | 0.240 |
Why?
|
| Indium Radioisotopes | 5 | 1991 | 24 | 0.240 |
Why?
|
| Radiotherapy Dosage | 13 | 2007 | 246 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 7 | 2015 | 283 | 0.230 |
Why?
|
| Boronic Acids | 1 | 2004 | 33 | 0.230 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 431 | 0.230 |
Why?
|
| Committee Membership | 1 | 2003 | 2 | 0.230 |
Why?
|
| Leukemia, Lymphoid | 7 | 1987 | 27 | 0.230 |
Why?
|
| Volatile Organic Compounds | 3 | 2013 | 45 | 0.230 |
Why?
|
| Pyrazines | 1 | 2004 | 70 | 0.230 |
Why?
|
| Organophosphorus Compounds | 1 | 2004 | 72 | 0.230 |
Why?
|
| Transplantation, Heterologous | 9 | 2006 | 187 | 0.220 |
Why?
|
| Organizational Objectives | 1 | 2003 | 71 | 0.220 |
Why?
|
| United States | 21 | 2020 | 12304 | 0.220 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 4442 | 0.220 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 845 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 23 | 2001 | 1485 | 0.220 |
Why?
|
| Anticarcinogenic Agents | 1 | 2004 | 67 | 0.220 |
Why?
|
| Oncogene Addiction | 1 | 2023 | 5 | 0.220 |
Why?
|
| HTLV-I Infections | 2 | 1996 | 21 | 0.220 |
Why?
|
| Neoplasm Transplantation | 11 | 2004 | 235 | 0.210 |
Why?
|
| Retrospective Studies | 17 | 2019 | 12633 | 0.210 |
Why?
|
| Receptor, ErbB-3 | 3 | 2009 | 42 | 0.210 |
Why?
|
| Penicillins | 22 | 1969 | 52 | 0.210 |
Why?
|
| Cluster Analysis | 4 | 2016 | 465 | 0.210 |
Why?
|
| Iodine Radioisotopes | 5 | 1992 | 126 | 0.210 |
Why?
|
| Doxorubicin | 21 | 2002 | 290 | 0.210 |
Why?
|
| Organoplatinum Compounds | 3 | 2006 | 40 | 0.210 |
Why?
|
| Growth Substances | 4 | 2000 | 136 | 0.200 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 148 | 0.200 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2002 | 34 | 0.200 |
Why?
|
| Biopsy | 12 | 2023 | 1056 | 0.200 |
Why?
|
| Airway Obstruction | 2 | 2003 | 168 | 0.200 |
Why?
|
| Carcinoma, Bronchogenic | 10 | 1984 | 17 | 0.200 |
Why?
|
| Aniline Compounds | 1 | 2022 | 71 | 0.200 |
Why?
|
| Quality of Life | 5 | 2022 | 2388 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 54 | 0.200 |
Why?
|
| Roxithromycin | 1 | 2001 | 1 | 0.200 |
Why?
|
| Iloprost | 2 | 2012 | 46 | 0.200 |
Why?
|
| Research Design | 7 | 2008 | 946 | 0.200 |
Why?
|
| DNA, Neoplasm | 8 | 2013 | 157 | 0.190 |
Why?
|
| Biological Products | 2 | 2023 | 172 | 0.190 |
Why?
|
| Prospective Studies | 15 | 2023 | 6276 | 0.190 |
Why?
|
| Neprilysin | 2 | 1998 | 47 | 0.190 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2017 | 16 | 0.190 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2018 | 84 | 0.190 |
Why?
|
| Cell Line | 24 | 2000 | 2651 | 0.190 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2019 | 26 | 0.190 |
Why?
|
| Diarrhea | 1 | 2022 | 173 | 0.190 |
Why?
|
| Pleural Neoplasms | 2 | 2016 | 18 | 0.180 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2014 | 139 | 0.180 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2001 | 96 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2022 | 193 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2003 | 684 | 0.180 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 156 | 0.180 |
Why?
|
| Patient Participation | 1 | 2003 | 363 | 0.180 |
Why?
|
| Ki-67 Antigen | 4 | 2015 | 104 | 0.170 |
Why?
|
| Oncogenes | 4 | 2016 | 104 | 0.170 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 4 | 2012 | 19 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 197 | 0.170 |
Why?
|
| GTP Phosphohydrolases | 3 | 2015 | 66 | 0.170 |
Why?
|
| Carcinoma, Large Cell | 4 | 2012 | 14 | 0.170 |
Why?
|
| Vaping | 1 | 2020 | 46 | 0.170 |
Why?
|
| Lymph Nodes | 17 | 1991 | 423 | 0.170 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 83 | 0.170 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2012 | 199 | 0.170 |
Why?
|
| Epidermal Growth Factor | 4 | 2013 | 161 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2016 | 816 | 0.170 |
Why?
|
| Aminoquinolines | 1 | 2019 | 20 | 0.160 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 73 | 0.160 |
Why?
|
| Breast Neoplasms | 8 | 2018 | 1872 | 0.160 |
Why?
|
| Bronchoscopy | 9 | 2019 | 245 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1405 | 0.160 |
Why?
|
| Young Adult | 10 | 2020 | 10518 | 0.160 |
Why?
|
| Friends | 1 | 2019 | 46 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2011 | 2129 | 0.160 |
Why?
|
| Structure-Activity Relationship | 6 | 2018 | 511 | 0.160 |
Why?
|
| Homeodomain Proteins | 3 | 2010 | 465 | 0.160 |
Why?
|
| Gene Expression | 6 | 2008 | 1436 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2004 | 182 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2019 | 162 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2004 | 58 | 0.150 |
Why?
|
| Wasting Syndrome | 1 | 1998 | 11 | 0.150 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 1996 | 13 | 0.150 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2010 | 58 | 0.150 |
Why?
|
| Caspase 3 | 2 | 2018 | 237 | 0.150 |
Why?
|
| Interferon-alpha | 4 | 1995 | 186 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2018 | 35 | 0.150 |
Why?
|
| Forecasting | 4 | 2003 | 334 | 0.150 |
Why?
|
| Lung Injury | 1 | 2020 | 199 | 0.150 |
Why?
|
| Proto-Oncogenes | 2 | 2014 | 26 | 0.150 |
Why?
|
| Smoking Cessation | 3 | 2019 | 377 | 0.150 |
Why?
|
| CpG Islands | 1 | 2018 | 118 | 0.150 |
Why?
|
| Multiple Myeloma | 5 | 1997 | 93 | 0.150 |
Why?
|
| Folic Acid | 4 | 2002 | 159 | 0.150 |
Why?
|
| Lung Diseases | 6 | 2015 | 710 | 0.150 |
Why?
|
| Cranial Irradiation | 2 | 1995 | 66 | 0.150 |
Why?
|
| Palliative Care | 6 | 2003 | 642 | 0.150 |
Why?
|
| Age Factors | 6 | 2016 | 2911 | 0.150 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 345 | 0.150 |
Why?
|
| Cyclophosphamide | 19 | 2001 | 218 | 0.150 |
Why?
|
| Clinical Protocols | 1 | 2019 | 233 | 0.150 |
Why?
|
| Vitamin B 12 | 3 | 2002 | 115 | 0.150 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 60 | 0.150 |
Why?
|
| Bone Marrow | 10 | 1992 | 249 | 0.150 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 1088 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 449 | 0.140 |
Why?
|
| HLA Antigens | 4 | 1988 | 223 | 0.140 |
Why?
|
| Receptors, KIR2DL3 | 1 | 2016 | 8 | 0.140 |
Why?
|
| Receptors, KIR2DL4 | 1 | 2016 | 3 | 0.140 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2016 | 18 | 0.140 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2016 | 16 | 0.140 |
Why?
|
| Patients | 1 | 2018 | 164 | 0.140 |
Why?
|
| Interleukin-2 | 3 | 1995 | 417 | 0.140 |
Why?
|
| Polyploidy | 1 | 2016 | 16 | 0.140 |
Why?
|
| Empathy | 2 | 2009 | 140 | 0.140 |
Why?
|
| RNA, Messenger | 7 | 2014 | 2574 | 0.140 |
Why?
|
| DNA Mutational Analysis | 6 | 2017 | 372 | 0.140 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 187 | 0.140 |
Why?
|
| Computational Biology | 2 | 2018 | 537 | 0.140 |
Why?
|
| Genes, myc | 1 | 2016 | 47 | 0.140 |
Why?
|
| Bone Neoplasms | 4 | 2015 | 194 | 0.140 |
Why?
|
| Genetic Therapy | 4 | 2015 | 260 | 0.130 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2016 | 14 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2016 | 93 | 0.130 |
Why?
|
| Drug Evaluation | 14 | 1992 | 79 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2016 | 3580 | 0.130 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1996 | 13 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 111 | 0.130 |
Why?
|
| Cohort Studies | 9 | 2019 | 4949 | 0.130 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1996 | 23 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2016 | 84 | 0.130 |
Why?
|
| Dimerization | 3 | 2002 | 177 | 0.130 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 54 | 0.130 |
Why?
|
| Membrane Proteins | 3 | 2015 | 1024 | 0.130 |
Why?
|
| Molecular Biology | 1 | 2016 | 56 | 0.130 |
Why?
|
| Radiosurgery | 2 | 2014 | 298 | 0.130 |
Why?
|
| Sex Factors | 6 | 2015 | 1739 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 1999 | 535 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2016 | 261 | 0.130 |
Why?
|
| DNA Methylation | 2 | 2018 | 499 | 0.130 |
Why?
|
| Antibodies, Viral | 11 | 2022 | 527 | 0.130 |
Why?
|
| Remission Induction | 7 | 2019 | 240 | 0.120 |
Why?
|
| Ifosfamide | 4 | 2008 | 32 | 0.120 |
Why?
|
| Prevalence | 4 | 2023 | 2269 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2001 | 70 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 140 | 0.120 |
Why?
|
| Patient-Specific Modeling | 1 | 2014 | 37 | 0.120 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2019 | 330 | 0.120 |
Why?
|
| Up-Regulation | 3 | 2002 | 820 | 0.120 |
Why?
|
| Biosensing Techniques | 2 | 2013 | 102 | 0.120 |
Why?
|
| Amino Acid Sequence | 6 | 1999 | 2000 | 0.120 |
Why?
|
| HIV | 1 | 1996 | 209 | 0.120 |
Why?
|
| Administration, Oral | 5 | 2012 | 734 | 0.120 |
Why?
|
| Transcription Factors | 3 | 2010 | 1528 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2015 | 81 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2011 | 382 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 141 | 0.120 |
Why?
|
| Correction of Hearing Impairment | 1 | 2014 | 13 | 0.120 |
Why?
|
| Drug Synergism | 4 | 2016 | 317 | 0.110 |
Why?
|
| Tomography, Spiral Computed | 1 | 2013 | 24 | 0.110 |
Why?
|
| Attitude to Computers | 1 | 2014 | 27 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 49 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 353 | 0.110 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2014 | 45 | 0.110 |
Why?
|
| Persons With Hearing Impairments | 1 | 2014 | 22 | 0.110 |
Why?
|
| Interferon-gamma | 3 | 1995 | 726 | 0.110 |
Why?
|
| PUVA Therapy | 3 | 1990 | 5 | 0.110 |
Why?
|
| Physicians | 2 | 2019 | 776 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2015 | 400 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2013 | 77 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 732 | 0.110 |
Why?
|
| Retroviridae | 9 | 1983 | 89 | 0.110 |
Why?
|
| Deltaretrovirus Infections | 3 | 1988 | 6 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 4 | 2014 | 193 | 0.110 |
Why?
|
| Wnt Proteins | 2 | 2012 | 135 | 0.110 |
Why?
|
| Software | 1 | 2017 | 541 | 0.110 |
Why?
|
| Hearing Aids | 1 | 2014 | 68 | 0.110 |
Why?
|
| Hypogonadism | 1 | 2013 | 74 | 0.100 |
Why?
|
| DNA | 6 | 1983 | 1356 | 0.100 |
Why?
|
| Hyperplasia | 2 | 2011 | 166 | 0.100 |
Why?
|
| Risk Factors | 9 | 2019 | 8702 | 0.100 |
Why?
|
| Risk Assessment | 5 | 2010 | 2990 | 0.100 |
Why?
|
| Radioimmunotherapy | 1 | 1992 | 10 | 0.100 |
Why?
|
| Prostatic Neoplasms | 5 | 2018 | 927 | 0.100 |
Why?
|
| Neurosecretory Systems | 2 | 2017 | 32 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2017 | 880 | 0.100 |
Why?
|
| Androgens | 1 | 2013 | 165 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 930 | 0.100 |
Why?
|
| Histones | 1 | 2016 | 540 | 0.100 |
Why?
|
| Benzamides | 1 | 2012 | 168 | 0.100 |
Why?
|
| Meningeal Neoplasms | 4 | 1986 | 88 | 0.100 |
Why?
|
| Patient Selection | 6 | 2008 | 654 | 0.100 |
Why?
|
| Molecular Sequence Data | 6 | 1999 | 2790 | 0.090 |
Why?
|
| Cognition | 2 | 2009 | 981 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2002 | 46 | 0.090 |
Why?
|
| Cetuximab | 3 | 2008 | 90 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2011 | 53 | 0.090 |
Why?
|
| Transcriptome | 1 | 2016 | 736 | 0.090 |
Why?
|
| Deltaretrovirus | 6 | 1986 | 12 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2015 | 76 | 0.090 |
Why?
|
| MAP Kinase Kinase 1 | 3 | 2015 | 66 | 0.090 |
Why?
|
| Antibiotics, Antitubercular | 11 | 1961 | 35 | 0.090 |
Why?
|
| Antibody Formation | 2 | 2022 | 273 | 0.090 |
Why?
|
| Gold | 1 | 2011 | 107 | 0.090 |
Why?
|
| Hearing Loss | 1 | 2014 | 183 | 0.090 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 2 | 2010 | 23 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2005 | 447 | 0.090 |
Why?
|
| Isoenzymes | 2 | 2004 | 285 | 0.090 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.090 |
Why?
|
| Radionuclide Imaging | 13 | 1991 | 121 | 0.090 |
Why?
|
| Mucins | 1 | 1990 | 61 | 0.090 |
Why?
|
| Dermatologic Agents | 11 | 1961 | 57 | 0.090 |
Why?
|
| Tuberculosis | 19 | 1970 | 244 | 0.090 |
Why?
|
| Testosterone | 1 | 2013 | 337 | 0.090 |
Why?
|
| Staphylococcal Infections | 7 | 1981 | 337 | 0.090 |
Why?
|
| Indium | 5 | 1987 | 10 | 0.090 |
Why?
|
| Placebos | 3 | 2019 | 197 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 86 | 0.080 |
Why?
|
| Random Allocation | 7 | 2017 | 337 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2012 | 291 | 0.080 |
Why?
|
| Expressed Emotion | 1 | 2009 | 18 | 0.080 |
Why?
|
| Isotretinoin | 1 | 2009 | 22 | 0.080 |
Why?
|
| Tumor Virus Infections | 3 | 1984 | 41 | 0.080 |
Why?
|
| Tocopherols | 1 | 2009 | 22 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 4 | 2001 | 30 | 0.080 |
Why?
|
| Central Nervous System Diseases | 2 | 1983 | 61 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2011 | 308 | 0.080 |
Why?
|
| Blotting, Western | 6 | 2014 | 1153 | 0.080 |
Why?
|
| Kanamycin | 6 | 1970 | 8 | 0.080 |
Why?
|
| MicroRNAs | 2 | 2012 | 607 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 277 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 2824 | 0.080 |
Why?
|
| Rats | 6 | 2005 | 5033 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 4 | 1986 | 40 | 0.080 |
Why?
|
| Fluorenes | 1 | 2009 | 38 | 0.080 |
Why?
|
| Vincristine | 13 | 1989 | 96 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2007 | 1098 | 0.080 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2008 | 63 | 0.080 |
Why?
|
| Cell Survival | 5 | 2013 | 1024 | 0.080 |
Why?
|
| Podophyllotoxin | 3 | 2003 | 7 | 0.080 |
Why?
|
| Aneuploidy | 5 | 2010 | 86 | 0.080 |
Why?
|
| Lymphatic Metastasis | 6 | 2020 | 276 | 0.080 |
Why?
|
| Amides | 1 | 2009 | 88 | 0.080 |
Why?
|
| Rats, Nude | 4 | 2003 | 27 | 0.080 |
Why?
|
| Topotecan | 2 | 2017 | 14 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 1996 | 107 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 4 | 2004 | 1168 | 0.080 |
Why?
|
| Multigene Family | 2 | 2006 | 193 | 0.080 |
Why?
|
| Social Perception | 1 | 2009 | 95 | 0.080 |
Why?
|
| Antisocial Personality Disorder | 1 | 2009 | 158 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 683 | 0.080 |
Why?
|
| Sample Size | 1 | 2008 | 115 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2011 | 315 | 0.070 |
Why?
|
| Inflammation | 1 | 2018 | 2500 | 0.070 |
Why?
|
| Radiography | 8 | 2002 | 828 | 0.070 |
Why?
|
| Kinetics | 8 | 1991 | 1569 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 621 | 0.070 |
Why?
|
| Epithelial Cells | 4 | 2007 | 961 | 0.070 |
Why?
|
| Chromosome Aberrations | 6 | 1993 | 134 | 0.070 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 1441 | 0.070 |
Why?
|
| Models, Statistical | 1 | 1991 | 606 | 0.070 |
Why?
|
| Exons | 2 | 2019 | 300 | 0.070 |
Why?
|
| Incidence | 3 | 2018 | 2335 | 0.070 |
Why?
|
| Bombesin | 3 | 1994 | 14 | 0.070 |
Why?
|
| Immunoglobulins | 2 | 1985 | 147 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2008 | 162 | 0.070 |
Why?
|
| Receptors, Growth Factor | 2 | 1997 | 49 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 301 | 0.070 |
Why?
|
| Epitopes | 3 | 1986 | 438 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2007 | 123 | 0.070 |
Why?
|
| Cytokines | 4 | 1997 | 1853 | 0.070 |
Why?
|
| Congresses as Topic | 3 | 2020 | 204 | 0.070 |
Why?
|
| Databases, Genetic | 2 | 2018 | 208 | 0.070 |
Why?
|
| Bevacizumab | 1 | 2007 | 118 | 0.070 |
Why?
|
| Radioisotopes | 4 | 1987 | 34 | 0.070 |
Why?
|
| Mesoderm | 1 | 2007 | 138 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1987 | 58 | 0.070 |
Why?
|
| Radioimmunoassay | 3 | 1986 | 163 | 0.070 |
Why?
|
| Aging | 2 | 2014 | 1632 | 0.070 |
Why?
|
| Tegafur | 1 | 2005 | 3 | 0.070 |
Why?
|
| Immunologic Factors | 3 | 1996 | 220 | 0.070 |
Why?
|
| Adolescent | 10 | 2020 | 17922 | 0.070 |
Why?
|
| Platinum Compounds | 1 | 2005 | 11 | 0.070 |
Why?
|
| Uracil | 1 | 2005 | 31 | 0.070 |
Why?
|
| Teniposide | 2 | 2003 | 3 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2001 | 356 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2003 | 119 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2005 | 277 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 1200 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 503 | 0.060 |
Why?
|
| Affect | 1 | 2007 | 244 | 0.060 |
Why?
|
| beta 2-Microglobulin | 1 | 1985 | 45 | 0.060 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2005 | 15 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 1001 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2006 | 142 | 0.060 |
Why?
|
| Anti-Infective Agents | 4 | 2001 | 225 | 0.060 |
Why?
|
| Drug Resistance | 5 | 2006 | 162 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 443 | 0.060 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2005 | 13 | 0.060 |
Why?
|
| G1 Phase | 1 | 2005 | 68 | 0.060 |
Why?
|
| Binding Sites, Antibody | 1 | 1984 | 36 | 0.060 |
Why?
|
| Radiation, Ionizing | 1 | 2005 | 73 | 0.060 |
Why?
|
| Selenium | 2 | 2004 | 31 | 0.060 |
Why?
|
| Injections, Subcutaneous | 3 | 2002 | 137 | 0.060 |
Why?
|
| Trastuzumab | 2 | 2002 | 89 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2003 | 959 | 0.060 |
Why?
|
| Drug Therapy | 5 | 1983 | 78 | 0.060 |
Why?
|
| Surveys and Questionnaires | 4 | 2014 | 4669 | 0.060 |
Why?
|
| Data Collection | 1 | 2007 | 636 | 0.060 |
Why?
|
| Bortezomib | 1 | 2004 | 41 | 0.060 |
Why?
|
| Animal Welfare | 1 | 2004 | 14 | 0.060 |
Why?
|
| Biological Therapy | 1 | 2004 | 26 | 0.060 |
Why?
|
| Radiotherapy | 6 | 1994 | 177 | 0.060 |
Why?
|
| Retroviridae Infections | 4 | 1985 | 45 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2002 | 146 | 0.060 |
Why?
|
| Karyotyping | 6 | 1996 | 102 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 1976 | 97 | 0.060 |
Why?
|
| Vaccination | 2 | 2022 | 1210 | 0.060 |
Why?
|
| Retinoids | 1 | 2004 | 31 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 58 | 0.060 |
Why?
|
| Planning Techniques | 1 | 2003 | 13 | 0.060 |
Why?
|
| Decision Making, Organizational | 1 | 2003 | 25 | 0.060 |
Why?
|
| Immunologic Tests | 1 | 2023 | 16 | 0.060 |
Why?
|
| Nucleocapsid | 1 | 2023 | 17 | 0.060 |
Why?
|
| Lymphocytes | 1 | 1985 | 344 | 0.060 |
Why?
|
| Necrosis | 1 | 2004 | 210 | 0.060 |
Why?
|
| Biotechnology | 1 | 2004 | 46 | 0.060 |
Why?
|
| Transfection | 1 | 2006 | 866 | 0.060 |
Why?
|
| Vitamin E | 1 | 2004 | 110 | 0.060 |
Why?
|
| Immunotoxins | 2 | 1995 | 33 | 0.060 |
Why?
|
| Methotrexate | 11 | 1986 | 228 | 0.060 |
Why?
|
| Nervous System Neoplasms | 1 | 1983 | 2 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2012 | 1384 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 164 | 0.050 |
Why?
|
| Meninges | 4 | 1982 | 29 | 0.050 |
Why?
|
| Killer Cells, Natural | 2 | 1988 | 383 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 92 | 0.050 |
Why?
|
| Parents | 2 | 2009 | 1207 | 0.050 |
Why?
|
| Pandemics | 2 | 2022 | 1335 | 0.050 |
Why?
|
| Skin | 7 | 1987 | 662 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2017 | 167 | 0.050 |
Why?
|
| Methylmalonic Acid | 1 | 2002 | 58 | 0.050 |
Why?
|
| Proteome | 1 | 2006 | 345 | 0.050 |
Why?
|
| Stomach Neoplasms | 2 | 1982 | 66 | 0.050 |
Why?
|
| Fruit | 1 | 2003 | 127 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2002 | 793 | 0.050 |
Why?
|
| Vegetables | 1 | 2003 | 133 | 0.050 |
Why?
|
| Farnesyltranstransferase | 1 | 2002 | 21 | 0.050 |
Why?
|
| Metaplasia | 2 | 2018 | 54 | 0.050 |
Why?
|
| Streptozocin | 3 | 1983 | 16 | 0.050 |
Why?
|
| Autoradiography | 3 | 1981 | 71 | 0.050 |
Why?
|
| Injections, Intralesional | 1 | 2002 | 32 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2007 | 746 | 0.050 |
Why?
|
| Infusion Pumps | 1 | 2002 | 32 | 0.050 |
Why?
|
| Tetrazolium Salts | 1 | 2002 | 18 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 104 | 0.050 |
Why?
|
| Homocysteine | 1 | 2002 | 135 | 0.050 |
Why?
|
| Peptides | 3 | 2001 | 864 | 0.050 |
Why?
|
| SEER Program | 1 | 2003 | 195 | 0.050 |
Why?
|
| Hypercalcemia | 4 | 1986 | 21 | 0.050 |
Why?
|
| Dietary Supplements | 2 | 2004 | 458 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2002 | 41 | 0.050 |
Why?
|
| Antigen-Antibody Complex | 4 | 1986 | 88 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 249 | 0.050 |
Why?
|
| Metalloendopeptidases | 2 | 2002 | 55 | 0.050 |
Why?
|
| Mechlorethamine | 3 | 1994 | 64 | 0.050 |
Why?
|
| Mediastinal Neoplasms | 1 | 2002 | 32 | 0.050 |
Why?
|
| Testis | 1 | 2002 | 134 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2004 | 374 | 0.050 |
Why?
|
| Ciprofloxacin | 1 | 2001 | 23 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 110 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2019 | 1660 | 0.050 |
Why?
|
| HIV Infections | 1 | 1996 | 2474 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1985 | 630 | 0.050 |
Why?
|
| Leukopenia | 5 | 1995 | 27 | 0.050 |
Why?
|
| Pedigree | 3 | 2000 | 468 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2017 | 309 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2001 | 69 | 0.050 |
Why?
|
| Kinins | 1 | 2001 | 3 | 0.050 |
Why?
|
| Fluorescence | 1 | 2001 | 154 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 1984 | 59 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 239 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2004 | 847 | 0.050 |
Why?
|
| Leukemia, Plasma Cell | 1 | 1980 | 5 | 0.050 |
Why?
|
| Paraproteinemias | 1 | 1980 | 4 | 0.050 |
Why?
|
| Hypergammaglobulinemia | 1 | 1980 | 9 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 1730 | 0.050 |
Why?
|
| Cervical Vertebrae | 1 | 2002 | 106 | 0.050 |
Why?
|
| Plasmacytoma | 1 | 1980 | 10 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 3 | 1988 | 46 | 0.050 |
Why?
|
| Cell Count | 3 | 1996 | 305 | 0.050 |
Why?
|
| Microtubules | 1 | 2003 | 238 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 44 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 402 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1995 | 65 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2020 | 75 | 0.040 |
Why?
|
| Ploidies | 4 | 2003 | 17 | 0.040 |
Why?
|
| Antioxidants | 1 | 2004 | 533 | 0.040 |
Why?
|
| Algorithms | 3 | 2015 | 1500 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2020 | 353 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 78 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 445 | 0.040 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1999 | 36 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2000 | 748 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 301 | 0.040 |
Why?
|
| ELAV Proteins | 1 | 1999 | 17 | 0.040 |
Why?
|
| Sepsis | 3 | 1981 | 515 | 0.040 |
Why?
|
| Gene Transfer Techniques | 2 | 1998 | 148 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2000 | 200 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1979 | 37 | 0.040 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2002 | 225 | 0.040 |
Why?
|
| Stomach Diseases | 1 | 1979 | 19 | 0.040 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 617 | 0.040 |
Why?
|
| Streptomycin | 8 | 1954 | 13 | 0.040 |
Why?
|
| Light | 1 | 2001 | 337 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2012 | 3037 | 0.040 |
Why?
|
| Spinal Cord Injuries | 1 | 2002 | 173 | 0.040 |
Why?
|
| Electrons | 4 | 1989 | 72 | 0.040 |
Why?
|
| Stomach | 1 | 1979 | 101 | 0.040 |
Why?
|
| gamma Catenin | 1 | 2018 | 17 | 0.040 |
Why?
|
| Antibodies | 3 | 1990 | 374 | 0.040 |
Why?
|
| History, 20th Century | 2 | 1996 | 273 | 0.040 |
Why?
|
| Desmoglein 3 | 1 | 2018 | 17 | 0.040 |
Why?
|
| Administration, Topical | 2 | 1994 | 137 | 0.040 |
Why?
|
| Carcinoma | 4 | 2001 | 200 | 0.040 |
Why?
|
| Smokers | 1 | 2019 | 147 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2000 | 222 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2018 | 1390 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2000 | 274 | 0.040 |
Why?
|
| HIV Wasting Syndrome | 1 | 1998 | 4 | 0.040 |
Why?
|
| Pneumonia | 6 | 1968 | 576 | 0.040 |
Why?
|
| Skin Diseases | 2 | 1979 | 124 | 0.040 |
Why?
|
| Organoids | 1 | 2019 | 74 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 544 | 0.040 |
Why?
|
| Hematologic Diseases | 3 | 1995 | 57 | 0.040 |
Why?
|
| Bronchial Diseases | 1 | 2018 | 38 | 0.040 |
Why?
|
| Teaching | 1 | 2020 | 224 | 0.040 |
Why?
|
| Gastrin-Releasing Peptide | 2 | 1996 | 6 | 0.040 |
Why?
|
| Communicable Diseases | 4 | 1964 | 130 | 0.040 |
Why?
|
| Tissue Distribution | 5 | 1990 | 324 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2017 | 3 | 0.040 |
Why?
|
| Genes, p53 | 1 | 1998 | 62 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2017 | 17 | 0.040 |
Why?
|
| Type C Phospholipases | 1 | 1998 | 66 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2000 | 319 | 0.040 |
Why?
|
| North America | 1 | 1998 | 261 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 171 | 0.040 |
Why?
|
| Web Browser | 1 | 2017 | 12 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 19 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2017 | 85 | 0.040 |
Why?
|
| Demecolcine | 1 | 1976 | 2 | 0.040 |
Why?
|
| B-Lymphocytes | 5 | 1986 | 773 | 0.040 |
Why?
|
| Endocarditis, Subacute Bacterial | 3 | 1964 | 3 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 2420 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2017 | 321 | 0.030 |
Why?
|
| Risk | 5 | 2001 | 819 | 0.030 |
Why?
|
| Bronchial Neoplasms | 1 | 1996 | 14 | 0.030 |
Why?
|
| Platinum | 1 | 2016 | 40 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2007 | 182 | 0.030 |
Why?
|
| Tuberculosis, Ocular | 5 | 1954 | 5 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1996 | 129 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 139 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 154 | 0.030 |
Why?
|
| Diet | 1 | 2003 | 1074 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2017 | 178 | 0.030 |
Why?
|
| Mitogens | 4 | 1998 | 58 | 0.030 |
Why?
|
| Endocarditis | 3 | 1964 | 32 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 1999 | 362 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 1996 | 33 | 0.030 |
Why?
|
| Comorbidity | 2 | 2016 | 1473 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 407 | 0.030 |
Why?
|
| Drug Stability | 1 | 1996 | 152 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 222 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 560 | 0.030 |
Why?
|
| Premedication | 1 | 1995 | 36 | 0.030 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 1997 | 117 | 0.030 |
Why?
|
| Meningitis | 4 | 1974 | 74 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 2586 | 0.030 |
Why?
|
| Rabbits | 10 | 2005 | 752 | 0.030 |
Why?
|
| Growth Inhibitors | 2 | 2002 | 45 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 1976 | 173 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2018 | 253 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 1996 | 182 | 0.030 |
Why?
|
| Colorado | 2 | 2014 | 4116 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 26 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1996 | 142 | 0.030 |
Why?
|
| Interferon-beta | 1 | 1995 | 79 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1995 | 79 | 0.030 |
Why?
|
| HLA-A Antigens | 2 | 1985 | 50 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 1995 | 51 | 0.030 |
Why?
|
| Guinea Pigs | 3 | 2005 | 151 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 1996 | 95 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 2 | 1986 | 239 | 0.030 |
Why?
|
| HLA-C Antigens | 2 | 1985 | 33 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 148 | 0.030 |
Why?
|
| HLA-B Antigens | 2 | 1985 | 56 | 0.030 |
Why?
|
| Whole-Body Irradiation | 3 | 1991 | 72 | 0.030 |
Why?
|
| Photopheresis | 1 | 1994 | 9 | 0.030 |
Why?
|
| Antigens, Viral | 4 | 1984 | 177 | 0.030 |
Why?
|
| Mitomycin | 2 | 1992 | 27 | 0.030 |
Why?
|
| Glioma | 1 | 2018 | 296 | 0.030 |
Why?
|
| Proteins | 1 | 2000 | 920 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 1994 | 15 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 91 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 553 | 0.030 |
Why?
|
| Methoxsalen | 1 | 1994 | 4 | 0.030 |
Why?
|
| Substance P | 1 | 1994 | 44 | 0.030 |
Why?
|
| Ultraviolet Therapy | 1 | 1994 | 16 | 0.030 |
Why?
|
| gamma-Globulins | 2 | 1965 | 18 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 187 | 0.030 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1994 | 6 | 0.030 |
Why?
|
| Contraindications | 1 | 1994 | 86 | 0.030 |
Why?
|
| Military Medicine | 1 | 1996 | 93 | 0.030 |
Why?
|
| Research | 2 | 1994 | 396 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 962 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1998 | 839 | 0.030 |
Why?
|
| Pyridazines | 1 | 2014 | 46 | 0.030 |
Why?
|
| Serum Albumin | 2 | 2013 | 135 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 537 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2000 | 1316 | 0.030 |
Why?
|
| Micrococcus | 3 | 1958 | 4 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 3 | 1992 | 33 | 0.030 |
Why?
|
| Safety | 1 | 1995 | 298 | 0.030 |
Why?
|
| Staphylococcus | 3 | 1970 | 69 | 0.030 |
Why?
|
| Ileum | 2 | 2005 | 93 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 3122 | 0.030 |
Why?
|
| Endoscopy | 1 | 2015 | 247 | 0.030 |
Why?
|
| Urinary Tract Infections | 3 | 1970 | 136 | 0.030 |
Why?
|
| Muscle Denervation | 1 | 1973 | 9 | 0.030 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2013 | 47 | 0.030 |
Why?
|
| DNA Fingerprinting | 1 | 2013 | 27 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 317 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 1992 | 139 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 22 | 0.030 |
Why?
|
| In Vitro Techniques | 5 | 2002 | 1044 | 0.030 |
Why?
|
| Auditory Perception | 1 | 2014 | 101 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 217 | 0.030 |
Why?
|
| Solid Phase Microextraction | 1 | 2012 | 6 | 0.030 |
Why?
|
| Treatment Failure | 1 | 1994 | 332 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 1992 | 31 | 0.030 |
Why?
|
| DNA Primers | 2 | 2009 | 514 | 0.030 |
Why?
|
| Neuromuscular Junction | 1 | 1973 | 53 | 0.030 |
Why?
|
| Chromosome Banding | 4 | 1996 | 21 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 390 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2013 | 88 | 0.030 |
Why?
|
| Breath Tests | 1 | 2012 | 83 | 0.030 |
Why?
|
| Luteinizing Hormone | 1 | 2013 | 169 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2012 | 125 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 616 | 0.030 |
Why?
|
| Hearing | 1 | 2014 | 132 | 0.030 |
Why?
|
| International Cooperation | 2 | 2003 | 174 | 0.030 |
Why?
|
| Liver | 5 | 1987 | 1690 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 1992 | 7 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 4 | 1954 | 148 | 0.030 |
Why?
|
| Species Specificity | 2 | 2005 | 552 | 0.030 |
Why?
|
| Ionomycin | 1 | 1992 | 24 | 0.030 |
Why?
|
| Ricin | 1 | 1991 | 8 | 0.030 |
Why?
|
| Probability | 3 | 2009 | 294 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2013 | 214 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2013 | 137 | 0.030 |
Why?
|
| Pyridones | 1 | 2013 | 125 | 0.020 |
Why?
|
| Equipment Design | 1 | 2014 | 517 | 0.020 |
Why?
|
| Immunization, Passive | 2 | 2001 | 80 | 0.020 |
Why?
|
| Nanostructures | 1 | 2013 | 99 | 0.020 |
Why?
|
| Chromosome Deletion | 2 | 1982 | 95 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1995 | 479 | 0.020 |
Why?
|
| Properdin | 2 | 1962 | 8 | 0.020 |
Why?
|
| Radiometry | 1 | 1992 | 43 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 485 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1856 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2014 | 276 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 1959 | 112 | 0.020 |
Why?
|
| Immunosorbent Techniques | 1 | 1991 | 17 | 0.020 |
Why?
|
| Drug Hypersensitivity | 2 | 1970 | 86 | 0.020 |
Why?
|
| Laboratories | 2 | 1963 | 95 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 4448 | 0.020 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 1982 | 11 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1990 | 221 | 0.020 |
Why?
|
| Vimentin | 1 | 2011 | 57 | 0.020 |
Why?
|
| Japan | 2 | 2009 | 88 | 0.020 |
Why?
|
| Lomustine | 7 | 1986 | 14 | 0.020 |
Why?
|
| Iceland | 1 | 2011 | 6 | 0.020 |
Why?
|
| Perception | 1 | 2014 | 315 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1992 | 166 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 684 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 795 | 0.020 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2011 | 12 | 0.020 |
Why?
|
| Spain | 1 | 2011 | 34 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 296 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1991 | 54 | 0.020 |
Why?
|
| Netherlands | 1 | 2011 | 64 | 0.020 |
Why?
|
| Adsorption | 1 | 1991 | 125 | 0.020 |
Why?
|
| Databases, Factual | 1 | 1996 | 1139 | 0.020 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Motor Neurons | 1 | 1973 | 213 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 1994 | 262 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2002 | 1357 | 0.020 |
Why?
|
| Photochemotherapy | 2 | 1980 | 29 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 49 | 0.020 |
Why?
|
| Megakaryocytes | 3 | 1980 | 30 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 102 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 150 | 0.020 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1980 | 12 | 0.020 |
Why?
|
| Base Sequence | 2 | 2009 | 2114 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 1988 | 19 | 0.020 |
Why?
|
| Clone Cells | 3 | 1985 | 248 | 0.020 |
Why?
|
| Nervous System Diseases | 3 | 1985 | 253 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1994 | 701 | 0.020 |
Why?
|
| Nicotinic Acids | 3 | 1954 | 6 | 0.020 |
Why?
|
| Hemagglutination Tests | 2 | 1964 | 7 | 0.020 |
Why?
|
| Mitosis | 3 | 1981 | 164 | 0.020 |
Why?
|
| Niacin | 3 | 1954 | 19 | 0.020 |
Why?
|
| Bacterial Infections | 2 | 2001 | 222 | 0.020 |
Why?
|
| Down-Regulation | 1 | 1992 | 601 | 0.020 |
Why?
|
| Calcitriol | 2 | 1986 | 53 | 0.020 |
Why?
|
| Proteomics | 2 | 2007 | 859 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 646 | 0.020 |
Why?
|
| Deafness | 1 | 1970 | 78 | 0.020 |
Why?
|
| Diethylstilbestrol | 2 | 1986 | 8 | 0.020 |
Why?
|
| Isoniazid | 3 | 1954 | 52 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2009 | 135 | 0.020 |
Why?
|
| Thoracic Surgery | 1 | 2010 | 105 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1991 | 281 | 0.020 |
Why?
|
| Infusions, Parenteral | 2 | 1986 | 38 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 154 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 2 | 1986 | 330 | 0.020 |
Why?
|
| Ovary | 1 | 1990 | 190 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2002 | 2393 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 388 | 0.020 |
Why?
|
| Histocytochemistry | 3 | 1983 | 78 | 0.020 |
Why?
|
| Herpes Simplex | 2 | 1987 | 88 | 0.020 |
Why?
|
| Tuberculosis, Meningeal | 4 | 1964 | 6 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 391 | 0.020 |
Why?
|
| Immunophenotyping | 2 | 2001 | 277 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1987 | 398 | 0.020 |
Why?
|
| Bone Marrow Cells | 3 | 1980 | 268 | 0.020 |
Why?
|
| Tetracycline | 2 | 1958 | 11 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2008 | 298 | 0.020 |
Why?
|
| New South Wales | 1 | 2007 | 10 | 0.020 |
Why?
|
| Rosette Formation | 2 | 1987 | 16 | 0.020 |
Why?
|
| Queensland | 1 | 2007 | 39 | 0.020 |
Why?
|
| Eye | 3 | 1954 | 101 | 0.020 |
Why?
|
| Ampicillin | 2 | 1965 | 13 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 1958 | 44 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2010 | 369 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 1987 | 21 | 0.020 |
Why?
|
| Body Fluids | 2 | 1964 | 58 | 0.020 |
Why?
|
| Remission, Spontaneous | 4 | 1980 | 37 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 1989 | 319 | 0.020 |
Why?
|
| Hydrocortisone | 2 | 1981 | 273 | 0.020 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 1960 | 38 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 352 | 0.020 |
Why?
|
| Procarbazine | 5 | 1986 | 8 | 0.020 |
Why?
|
| Dyspnea | 2 | 1986 | 223 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 178 | 0.020 |
Why?
|
| California | 1 | 2008 | 367 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 750 | 0.020 |
Why?
|
| Child | 4 | 2009 | 18503 | 0.020 |
Why?
|
| Calcitonin | 1 | 1986 | 23 | 0.020 |
Why?
|
| Nucleotidases | 2 | 1985 | 7 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 1986 | 90 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2007 | 9138 | 0.020 |
Why?
|
| Genome | 1 | 2009 | 271 | 0.020 |
Why?
|
| Bacillus | 2 | 1957 | 14 | 0.020 |
Why?
|
| Phosphates | 2 | 1958 | 160 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 297 | 0.020 |
Why?
|
| DNA Repair | 1 | 2008 | 190 | 0.020 |
Why?
|
| Sulfadiazine | 1 | 1966 | 4 | 0.020 |
Why?
|
| Nocardia Infections | 1 | 1966 | 7 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 2 | 1957 | 46 | 0.020 |
Why?
|
| Insecta | 2 | 1957 | 65 | 0.020 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1986 | 19 | 0.020 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1986 | 13 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1966 | 49 | 0.020 |
Why?
|
| Farmer's Lung | 1 | 1965 | 3 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1986 | 82 | 0.020 |
Why?
|
| Erythromycin | 2 | 1958 | 24 | 0.020 |
Why?
|
| Mice, Inbred A | 1 | 2005 | 45 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2005 | 33 | 0.020 |
Why?
|
| Urea | 1 | 1966 | 69 | 0.020 |
Why?
|
| Deoxyribonucleosides | 1 | 1985 | 2 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1986 | 130 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 1986 | 100 | 0.020 |
Why?
|
| Cell Movement | 2 | 1981 | 867 | 0.020 |
Why?
|
| Peritonitis | 1 | 1966 | 76 | 0.020 |
Why?
|
| DNA Damage | 1 | 2008 | 357 | 0.020 |
Why?
|
| Freezing | 1 | 1986 | 85 | 0.020 |
Why?
|
| Mathematics | 1 | 1986 | 100 | 0.020 |
Why?
|
| Mycoses | 1 | 1966 | 67 | 0.020 |
Why?
|
| Blood | 1 | 1985 | 97 | 0.020 |
Why?
|
| HLA-B35 Antigen | 1 | 1985 | 3 | 0.020 |
Why?
|
| HLA-B8 Antigen | 1 | 1985 | 14 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1230 | 0.020 |
Why?
|
| Enzymes | 1 | 2005 | 61 | 0.020 |
Why?
|
| Bleomycin | 2 | 1978 | 232 | 0.020 |
Why?
|
| Phenylalanine | 1 | 2005 | 58 | 0.020 |
Why?
|
| Carcinogens | 1 | 2005 | 105 | 0.020 |
Why?
|
| Viral Proteins | 3 | 1981 | 286 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1985 | 189 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1985 | 85 | 0.020 |
Why?
|
| Haemophilus | 1 | 1965 | 4 | 0.020 |
Why?
|
| Lymphokines | 1 | 1985 | 115 | 0.020 |
Why?
|
| Mitomycins | 1 | 1984 | 3 | 0.020 |
Why?
|
| Myeloma Proteins | 1 | 1984 | 7 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 1985 | 69 | 0.020 |
Why?
|
| Endocytosis | 1 | 1986 | 152 | 0.020 |
Why?
|
| Melphalan | 1 | 1984 | 29 | 0.020 |
Why?
|
| Exanthema | 1 | 2005 | 77 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 1985 | 115 | 0.020 |
Why?
|
| Carmustine | 1 | 1984 | 47 | 0.020 |
Why?
|
| Monocytes | 2 | 1985 | 507 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 1965 | 36 | 0.010 |
Why?
|
| Tyrosine | 1 | 2005 | 219 | 0.010 |
Why?
|
| Syndrome | 3 | 1984 | 339 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1218 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1984 | 117 | 0.010 |
Why?
|
| DNA Replication | 1 | 2005 | 203 | 0.010 |
Why?
|
| Acute Disease | 2 | 1984 | 914 | 0.010 |
Why?
|
| Psychology, Child | 1 | 2004 | 37 | 0.010 |
Why?
|
| Hemagglutination | 1 | 1964 | 7 | 0.010 |
Why?
|
| Bronchopneumonia | 1 | 1964 | 5 | 0.010 |
Why?
|
| Nephritis, Interstitial | 1 | 1984 | 7 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1984 | 42 | 0.010 |
Why?
|
| Acetaminophen | 1 | 1987 | 237 | 0.010 |
Why?
|
| Expectorants | 1 | 1964 | 24 | 0.010 |
Why?
|
| Nephrosis, Lipoid | 1 | 1984 | 10 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 274 | 0.010 |
Why?
|
| Prednisone | 1 | 1984 | 232 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1983 | 52 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 296 | 0.010 |
Why?
|
| Densitometry | 2 | 1980 | 29 | 0.010 |
Why?
|
| Chromosomes | 2 | 1982 | 85 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2003 | 15 | 0.010 |
Why?
|
| Cell Transformation, Viral | 2 | 1984 | 24 | 0.010 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1983 | 13 | 0.010 |
Why?
|
| Toxicology | 1 | 1964 | 36 | 0.010 |
Why?
|
| Muscles | 3 | 1982 | 326 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1966 | 200 | 0.010 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2003 | 17 | 0.010 |
Why?
|
| Vital Capacity | 1 | 2004 | 277 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 2 | 1957 | 271 | 0.010 |
Why?
|
| Growth Hormone | 2 | 1954 | 99 | 0.010 |
Why?
|
| Vitamins | 1 | 2004 | 151 | 0.010 |
Why?
|
| Biopsy, Needle | 2 | 1982 | 183 | 0.010 |
Why?
|
| Cloxacillin | 1 | 1963 | 1 | 0.010 |
Why?
|
| Pneumococcal Infections | 2 | 1956 | 91 | 0.010 |
Why?
|
| Tuberculosis, Miliary | 3 | 1964 | 5 | 0.010 |
Why?
|
| Furunculosis | 1 | 1962 | 1 | 0.010 |
Why?
|
| Drainage | 1 | 1964 | 151 | 0.010 |
Why?
|
| Sex Ratio | 1 | 1983 | 14 | 0.010 |
Why?
|
| Razoxane | 1 | 1982 | 1 | 0.010 |
Why?
|
| Receptors, Bradykinin | 1 | 2002 | 4 | 0.010 |
Why?
|
| Transfer Factor | 1 | 1983 | 24 | 0.010 |
Why?
|
| Thymosin | 2 | 1980 | 5 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1983 | 25 | 0.010 |
Why?
|
| Lymphocyte Activation | 3 | 1983 | 1057 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 88 | 0.010 |
Why?
|
| Cell Membrane | 2 | 2002 | 683 | 0.010 |
Why?
|
| Antilymphocyte Serum | 1 | 1983 | 66 | 0.010 |
Why?
|
| Allergy and Immunology | 1 | 1964 | 56 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1983 | 156 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1965 | 132 | 0.010 |
Why?
|
| Pentosyltransferases | 1 | 1982 | 3 | 0.010 |
Why?
|
| Nucleoside Deaminases | 1 | 1982 | 2 | 0.010 |
Why?
|
| Bacteriophages | 2 | 1961 | 76 | 0.010 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 1982 | 5 | 0.010 |
Why?
|
| Autopsy | 1 | 1983 | 86 | 0.010 |
Why?
|
| Cells, Cultured | 7 | 1985 | 3914 | 0.010 |
Why?
|
| Cysteine | 1 | 1964 | 173 | 0.010 |
Why?
|
| Keratins | 1 | 2003 | 176 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 1982 | 24 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 1984 | 262 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2004 | 516 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2004 | 168 | 0.010 |
Why?
|
| Umbilical Cord | 1 | 2002 | 80 | 0.010 |
Why?
|
| Aggression | 1 | 2004 | 185 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 1982 | 45 | 0.010 |
Why?
|
| Agglutinins | 1 | 1962 | 2 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 1982 | 11 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 1982 | 26 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1982 | 8 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1982 | 30 | 0.010 |
Why?
|
| Sulfonamides | 2 | 1955 | 447 | 0.010 |
Why?
|
| Manipulation, Spinal | 1 | 2002 | 8 | 0.010 |
Why?
|
| Caspases | 1 | 2003 | 245 | 0.010 |
Why?
|
| Complement System Proteins | 2 | 1962 | 288 | 0.010 |
Why?
|
| Rectal Diseases | 1 | 1981 | 17 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 2 | 1980 | 123 | 0.010 |
Why?
|
| Bone Resorption | 1 | 1982 | 74 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1983 | 224 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2002 | 109 | 0.010 |
Why?
|
| Phenotype | 4 | 1984 | 2839 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1983 | 203 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 1122 | 0.010 |
Why?
|
| Immune System | 1 | 1983 | 173 | 0.010 |
Why?
|
| Glasgow Coma Scale | 1 | 2002 | 144 | 0.010 |
Why?
|
| CD52 Antigen | 1 | 2001 | 3 | 0.010 |
Why?
|
| Oculomotor Muscles | 2 | 1951 | 40 | 0.010 |
Why?
|
| Alemtuzumab | 1 | 2001 | 12 | 0.010 |
Why?
|
| Zymosan | 1 | 1961 | 63 | 0.010 |
Why?
|
| APUD Cells | 1 | 1980 | 1 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2001 | 255 | 0.010 |
Why?
|
| Furocoumarins | 1 | 1980 | 8 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2000 | 38 | 0.010 |
Why?
|
| Polysaccharides | 1 | 1961 | 80 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 133 | 0.010 |
Why?
|
| Leukocytes | 2 | 1984 | 281 | 0.010 |
Why?
|
| Amyloidosis | 1 | 1980 | 36 | 0.010 |
Why?
|
| Intestinal Neoplasms | 1 | 1980 | 24 | 0.010 |
Why?
|
| Hospitals, Chronic Disease | 2 | 1958 | 2 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1980 | 72 | 0.010 |
Why?
|
| Piperazines | 1 | 1982 | 314 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2001 | 105 | 0.010 |
Why?
|
| Biological Assay | 1 | 2001 | 114 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1980 | 23 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 1980 | 39 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1981 | 90 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 1964 | 260 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 1966 | 649 | 0.010 |
Why?
|
| Bacteremia | 1 | 1962 | 159 | 0.010 |
Why?
|
| Brain | 3 | 1985 | 2373 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2002 | 315 | 0.010 |
Why?
|
| Health Resources | 1 | 2001 | 122 | 0.010 |
Why?
|
| Influenza, Human | 1 | 1985 | 548 | 0.010 |
Why?
|
| Disease Management | 1 | 1964 | 563 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 2002 | 354 | 0.010 |
Why?
|
| Joint Instability | 1 | 2002 | 166 | 0.010 |
Why?
|
| Thymus Hormones | 1 | 1979 | 1 | 0.010 |
Why?
|
| Carcinogens, Environmental | 1 | 1979 | 7 | 0.010 |
Why?
|
| Stomach Ulcer | 1 | 1979 | 9 | 0.010 |
Why?
|
| Gastroscopy | 1 | 1979 | 18 | 0.010 |
Why?
|
| Duodenal Ulcer | 1 | 1979 | 10 | 0.010 |
Why?
|
| Osteoporosis | 1 | 1982 | 227 | 0.010 |
Why?
|
| Spinal Cord | 1 | 1982 | 351 | 0.010 |
Why?
|
| History, 19th Century | 1 | 1979 | 56 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2001 | 309 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1980 | 130 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 548 | 0.010 |
Why?
|
| Blood Platelets | 2 | 1984 | 350 | 0.010 |
Why?
|
| Hybridomas | 2 | 1994 | 230 | 0.010 |
Why?
|
| Spinal Cord Compression | 1 | 1978 | 17 | 0.010 |
Why?
|
| Demeclocycline | 1 | 1978 | 3 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2000 | 390 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2001 | 442 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1998 | 27 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 1180 | 0.010 |
Why?
|
| Gastritis | 1 | 1979 | 84 | 0.010 |
Why?
|
| Phospholipase C beta | 1 | 1998 | 25 | 0.010 |
Why?
|
| Chloramphenicol | 1 | 1958 | 6 | 0.010 |
Why?
|
| Levamisole | 1 | 1998 | 20 | 0.010 |
Why?
|
| Estradiol | 1 | 1981 | 452 | 0.010 |
Why?
|
| Vasopressins | 1 | 1978 | 57 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1979 | 127 | 0.010 |
Why?
|
| Antibody Specificity | 3 | 1983 | 176 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1980 | 342 | 0.010 |
Why?
|
| Cell Separation | 3 | 1986 | 293 | 0.010 |
Why?
|
| Hormones, Ectopic | 1 | 1977 | 2 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1979 | 129 | 0.010 |
Why?
|
| Pregnancy | 1 | 1989 | 5553 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1998 | 151 | 0.010 |
Why?
|
| GPI-Linked Proteins | 1 | 1997 | 54 | 0.010 |
Why?
|
| Thoracotomy | 1 | 1997 | 67 | 0.010 |
Why?
|
| Amantadine | 2 | 1968 | 7 | 0.010 |
Why?
|
| Vinca Alkaloids | 1 | 1976 | 1 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 325 | 0.010 |
Why?
|
| Capsules | 1 | 1957 | 36 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 1994 | 781 | 0.010 |
Why?
|
| Cephalosporins | 2 | 1968 | 26 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1977 | 139 | 0.010 |
Why?
|
| Penicillin V | 1 | 1956 | 3 | 0.010 |
Why?
|
| Gentamicins | 2 | 1968 | 42 | 0.010 |
Why?
|
| Cycloserine | 1 | 1956 | 3 | 0.010 |
Why?
|
| Colchicine | 1 | 1976 | 24 | 0.010 |
Why?
|
| Novobiocin | 1 | 1956 | 5 | 0.010 |
Why?
|
| Maryland | 1 | 1996 | 37 | 0.010 |
Why?
|
| Computer Communication Networks | 1 | 1996 | 32 | 0.010 |
Why?
|
| Gallium Radioisotopes | 1 | 1975 | 19 | 0.010 |
Why?
|
| Laparoscopy | 1 | 1980 | 400 | 0.010 |
Why?
|
| Arthritis | 1 | 1957 | 111 | 0.010 |
Why?
|
| Sulfisoxazole | 1 | 1955 | 1 | 0.010 |
Why?
|
| Herpes Zoster | 1 | 1980 | 333 | 0.010 |
Why?
|
| Glycopeptides | 1 | 1996 | 43 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 1976 | 88 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1996 | 227 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1997 | 608 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1956 | 134 | 0.010 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 1994 | 5 | 0.010 |
Why?
|
| Portal System | 1 | 1953 | 13 | 0.010 |
Why?
|
| Phlebitis | 1 | 1953 | 11 | 0.010 |
Why?
|
| Respiratory Function Tests | 2 | 1986 | 535 | 0.010 |
Why?
|
| Leucomycins | 1 | 1953 | 1 | 0.010 |
Why?
|
| Dogs | 2 | 1987 | 341 | 0.010 |
Why?
|
| Veins | 1 | 1953 | 57 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1994 | 83 | 0.010 |
Why?
|
| Isomerism | 1 | 1953 | 42 | 0.010 |
Why?
|
| Heart Neoplasms | 1 | 1994 | 50 | 0.010 |
Why?
|
| Gallamine Triethiodide | 1 | 1973 | 1 | 0.010 |
Why?
|
| Edrophonium | 1 | 1973 | 2 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1994 | 273 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 1996 | 376 | 0.010 |
Why?
|
| Disease | 1 | 1953 | 87 | 0.010 |
Why?
|
| Human Growth Hormone | 1 | 1953 | 38 | 0.010 |
Why?
|
| Sciatic Nerve | 1 | 1973 | 56 | 0.010 |
Why?
|
| Cats | 1 | 1973 | 204 | 0.010 |
Why?
|
| Appendicitis | 1 | 1953 | 108 | 0.010 |
Why?
|
| Chromosomes, Human, 1-3 | 2 | 1982 | 2 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1992 | 80 | 0.010 |
Why?
|
| Meningitis, Pneumococcal | 1 | 1952 | 7 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1983 | 198 | 0.010 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1992 | 9 | 0.010 |
Why?
|
| Recurrence | 3 | 1980 | 953 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1973 | 263 | 0.010 |
Why?
|
| Models, Biological | 1 | 1979 | 1646 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1976 | 589 | 0.010 |
Why?
|
| Hormones | 1 | 1952 | 132 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1982 | 169 | 0.010 |
Why?
|
| Insulin | 1 | 1981 | 2082 | 0.010 |
Why?
|
| Perfusion | 1 | 1992 | 151 | 0.010 |
Why?
|
| Klebsiella | 1 | 1970 | 2 | 0.010 |
Why?
|
| Vestibulocochlear Nerve | 1 | 1970 | 6 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 1973 | 232 | 0.010 |
Why?
|
| Blood Cell Count | 2 | 1981 | 52 | 0.010 |
Why?
|
| Organ of Corti | 1 | 1970 | 14 | 0.010 |
Why?
|
| Kidney | 2 | 1984 | 1207 | 0.010 |
Why?
|
| Chlortetracycline | 1 | 1950 | 4 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1970 | 66 | 0.010 |
Why?
|
| Culture Media | 2 | 1981 | 156 | 0.010 |
Why?
|
| Injections | 1 | 1991 | 161 | 0.010 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1970 | 33 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1982 | 409 | 0.010 |
Why?
|
| Paralysis | 1 | 1970 | 67 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1973 | 397 | 0.010 |
Why?
|
| Action Potentials | 1 | 1973 | 410 | 0.010 |
Why?
|
| Promegestone | 1 | 1989 | 33 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1989 | 47 | 0.010 |
Why?
|
| Chickenpox | 1 | 1950 | 94 | 0.010 |
Why?
|
| Vomiting | 2 | 1981 | 125 | 0.010 |
Why?
|
| Neuromuscular Diseases | 1 | 1970 | 90 | 0.010 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1968 | 11 | 0.000 |
Why?
|
| Thrombocythemia, Essential | 1 | 1988 | 6 | 0.000 |
Why?
|
| Polymyxins | 1 | 1968 | 9 | 0.000 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1987 | 32 | 0.000 |
Why?
|
| Hepatic Insufficiency | 1 | 1947 | 4 | 0.000 |
Why?
|
| Infant | 1 | 1980 | 7979 | 0.000 |
Why?
|
| Whole-Body Counting | 1 | 1987 | 4 | 0.000 |
Why?
|
| Lysosomes | 1 | 1968 | 125 | 0.000 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1988 | 93 | 0.000 |
Why?
|
| Propidium | 1 | 1986 | 4 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1970 | 354 | 0.000 |
Why?
|
| Medroxyprogesterone | 1 | 1986 | 10 | 0.000 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1986 | 29 | 0.000 |
Why?
|
| Coloring Agents | 1 | 1986 | 71 | 0.000 |
Why?
|
| Orchiectomy | 1 | 1986 | 57 | 0.000 |
Why?
|
| Cephaloridine | 1 | 1966 | 1 | 0.000 |
Why?
|
| Immunoglobulin M | 1 | 1987 | 254 | 0.000 |
Why?
|
| Immunodiffusion | 1 | 1965 | 9 | 0.000 |
Why?
|
| Sulfanilamides | 2 | 1955 | 2 | 0.000 |
Why?
|
| Spleen | 1 | 1987 | 492 | 0.000 |
Why?
|
| Polymers | 1 | 1989 | 463 | 0.000 |
Why?
|
| Immunization | 1 | 1987 | 401 | 0.000 |
Why?
|
| Tuberculosis, Renal | 1 | 1964 | 1 | 0.000 |
Why?
|
| Canada | 1 | 1965 | 335 | 0.000 |
Why?
|
| Polyethylene Glycols | 1 | 1989 | 576 | 0.000 |
Why?
|
| Death, Sudden | 1 | 1964 | 33 | 0.000 |
Why?
|
| Purines | 1 | 1985 | 159 | 0.000 |
Why?
|
| Memory Disorders | 1 | 1985 | 155 | 0.000 |
Why?
|
| Pathology | 1 | 1964 | 21 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1984 | 329 | 0.000 |
Why?
|
| Cell Differentiation | 2 | 1985 | 1700 | 0.000 |
Why?
|
| Blood Cells | 1 | 1984 | 38 | 0.000 |
Why?
|
| Urticaria | 1 | 1984 | 51 | 0.000 |
Why?
|
| Respiratory Tract Infections | 1 | 1968 | 323 | 0.000 |
Why?
|
| Leucovorin | 1 | 1983 | 42 | 0.000 |
Why?
|
| West Indies | 1 | 1983 | 4 | 0.000 |
Why?
|
| Alabama | 1 | 1983 | 28 | 0.000 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1983 | 6 | 0.000 |
Why?
|
| Georgia | 1 | 1983 | 62 | 0.000 |
Why?
|
| Florida | 1 | 1983 | 73 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1983 | 87 | 0.000 |
Why?
|
| Skin Tests | 1 | 1983 | 130 | 0.000 |
Why?
|
| Warfarin | 1 | 1984 | 136 | 0.000 |
Why?
|
| Osteosclerosis | 1 | 1982 | 2 | 0.000 |
Why?
|
| Anemia, Sideroblastic | 1 | 1982 | 3 | 0.000 |
Why?
|
| Pulmonary Embolism | 1 | 1964 | 183 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1982 | 294 | 0.000 |
Why?
|
| Creatinine | 1 | 1983 | 430 | 0.000 |
Why?
|
| Agranulocytosis | 1 | 1981 | 31 | 0.000 |
Why?
|
| Adrenal Glands | 1 | 1982 | 72 | 0.000 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 1981 | 1 | 0.000 |
Why?
|
| Peripheral Nerves | 1 | 1982 | 65 | 0.000 |
Why?
|
| Viral Core Proteins | 1 | 1981 | 20 | 0.000 |
Why?
|
| Electrophysiology | 1 | 1982 | 202 | 0.000 |
Why?
|
| Diphosphates | 1 | 1981 | 16 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1949 | 902 | 0.000 |
Why?
|
| Technetium | 1 | 1981 | 22 | 0.000 |
Why?
|
| Transferrin | 1 | 1981 | 40 | 0.000 |
Why?
|
| Substance-Related Disorders | 1 | 1949 | 951 | 0.000 |
Why?
|
| Nausea | 1 | 1981 | 103 | 0.000 |
Why?
|
| Abscess | 1 | 1981 | 72 | 0.000 |
Why?
|
| Immune Sera | 1 | 1981 | 80 | 0.000 |
Why?
|
| Fluorometry | 1 | 1980 | 19 | 0.000 |
Why?
|
| Photomicrography | 1 | 1980 | 7 | 0.000 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1980 | 19 | 0.000 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1980 | 44 | 0.000 |
Why?
|
| Dermatitis, Exfoliative | 1 | 1980 | 4 | 0.000 |
Why?
|
| Haplorhini | 1 | 1980 | 60 | 0.000 |
Why?
|
| Purpura | 1 | 1980 | 12 | 0.000 |
Why?
|
| Castration | 1 | 1980 | 14 | 0.000 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 1980 | 14 | 0.000 |
Why?
|
| Alopecia | 1 | 1979 | 28 | 0.000 |
Why?
|
| Receptors, Complement | 1 | 1980 | 111 | 0.000 |
Why?
|
| Cocarcinogenesis | 1 | 1979 | 14 | 0.000 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1980 | 107 | 0.000 |
Why?
|
| Chemical Industry | 1 | 1979 | 9 | 0.000 |
Why?
|
| Methods | 1 | 1978 | 58 | 0.000 |
Why?
|
| Fiber Optic Technology | 1 | 1978 | 17 | 0.000 |
Why?
|
| Hemoglobins | 1 | 1981 | 312 | 0.000 |
Why?
|
| Pesticides | 1 | 1979 | 49 | 0.000 |
Why?
|
| Solvents | 1 | 1979 | 108 | 0.000 |
Why?
|
| Mucous Membrane | 1 | 1978 | 109 | 0.000 |
Why?
|
| Granulocytes | 1 | 1976 | 78 | 0.000 |
Why?
|
| Herpesvirus 3, Human | 1 | 1980 | 381 | 0.000 |
Why?
|
| Air Pollutants | 1 | 1979 | 246 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1983 | 2164 | 0.000 |
Why?
|
| Hospitals, University | 1 | 1946 | 172 | 0.000 |
Why?
|
| Biological Transport | 1 | 1946 | 375 | 0.000 |
Why?
|
| Minnesota | 1 | 1964 | 134 | 0.000 |
Why?
|
| Students | 1 | 1946 | 503 | 0.000 |
Why?
|